News
PRECIGEN's stock price rose 41.6% due to the approval of its immunotherapy for rare respiratory diseases by the U.S. Food and Drug Administration
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments